LONA
NASDAQLeonaBio Inc.
News · 26 weeks65-33%
2026-03-012026-08-23
Mix1690d
- Insider11(69%)
- Other2(13%)
- SEC Filings1(6%)
- Analyst1(6%)
- Leadership1(6%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13D/A filed by LeonaBio Inc.SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
- PRLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateOn Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 14, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2026, and provided recent pipeline and business updates. "We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3 trial and advancing lasofoxifene toward what we believe could b
- ANALYSTLeonaBio upgraded by Citizens with a new price targetCitizens upgraded LeonaBio from Mkt Perform to Mkt Outperform and set a new price target of $18.00
- INSIDERSEC Form 4 filed by Director Perceptive Advisors Llc4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Perceptive Advisors Llc4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Callori Fred4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Holles Natalie C.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Silverman Peter B.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Panzara Michael A.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Romano Kelly A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Edelman Joseph4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson James A4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Kosacz Barbara4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Pickering Grant4 - LeonaBio, Inc. (0001620463) (Issuer)
- SECLeonaBio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - LeonaBio, Inc. (0001620463) (Filer)
- PRLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitBOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Javier San Martin, MD, Chief Medical Officer of LeonaBio, delivered a presentation at the 5th Annual ALS Drug Development Summit taking place June 2-4, 2026 in Boston, Massachusetts. The presentation, titled "Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive Methodologies," provided an overview of the company's brelgometon (ATH-1105) clinical development program in amyotrophic lateral sclerosis (ALS). Brelgometon is an or
- ANALYSTPiper Sandler initiated coverage on LeonaBio with a new price targetPiper Sandler initiated coverage of LeonaBio with a rating of Overweight and set a new price target of $20.00
- PRLeonaBio to Participate in Upcoming Medical and Industry Meetings in JuneBOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA. Details are as follows: 5th Annual ALS Drug Development Summit Oral Presentation Title: Advancing ATH-1105 in ALS: Strategic Trial Design, Biomarker Integration & Adaptive MethodologiesSession Title: Redefining Biomarkers and Trial Design to Accelerate Neurodeg
- SECSEC Form DEFA14A filed by LeonaBio Inc.DEFA14A - LeonaBio, Inc. (0001620463) (Filer)
- SECSEC Form DEF 14A filed by LeonaBio Inc.DEF 14A - LeonaBio, Inc. (0001620463) (Filer)
- INSIDERSEC Form 4 filed by Director Holles Natalie C.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Silverman Peter B.4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Director Callori Fred4 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silverman Peter B.3 - LeonaBio, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 3 filed by new insider Holles Natalie C.3 - LeonaBio, Inc. (0001620463) (Issuer)
LONA FAQ
6 questionsWhere does LONA stock trade?
LeonaBio Inc. (LONA) is listed on NASDAQ.What sector and industry is LONA in?
LeonaBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did LeonaBio Inc. go public?
LeonaBio Inc. (LONA) completed its IPO in 2020.What are analysts saying about LONA?
LeonaBio Inc. has had 4 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $1800.00 price target on 2026-07-30. Recent price targets range from $1000.00 to $2000.00.What companies are similar to LONA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare LONA side-by-side with any of them on Quantisnow.How can I track LONA on Quantisnow?
Quantisnow aggregates LeonaBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LONA to receive live email and push alerts on every new disclosure.